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Background: Patients with high-risk neuroblastoma (NBL) tumors have a high mortality rate. Consequently, there is
an urgent need for the development of new treatments for this condition. Targeting death receptor signaling has
been proposed as an alternative to standard chemo- and radio-therapies in various tumors. In NBL, this therapeutic
strategy has been largely disregarded, possibly because ~50-70% of all human NBLs are characterized by caspase-8
silencing. However, the expression of caspase-8 is detected in a significant group of NBL patients, and they could
therefore benefit from treatments that induce cell death through death receptor activation. Given that cytokines,
such as TNFα, are able to upregulate Fas expression, we sought to address the therapeutic relevance of co-treatment
with TNFα and FasL in NBL.
Methods: For the purpose of the study we used a set of eight NBL cell lines. Here we explore the cell death induced
by TNFα, FasL, cisplatin, and etoposide, or a combination thereof by Hoechst staining and calcein viability assay.
Further assessment of the signaling pathways involved was performed by caspase activity assays and Western blot
experiments. Characterization of Fas expression levels was achieved by qRT-PCR, cell surface biotinylation assays,
and cytometry.
Results: We have found that TNFα is able to increase FasL-induced cell death by a mechanism that involves the
NF-κB-mediated induction of the Fas receptor. Moreover, TNFα sensitized NBL cells to DNA-damaging agents (i.e. cisplatin
and etoposide) that induce the expression of FasL. Priming to FasL-, cisplatin-, and etoposide-induced cell death could
only be achieved in NBLs that display TNFα-induced upregulation of Fas. Further analysis denotes that the high degree
of heterogeneity between NBLs is also manifested in Fas expression and modulation thereof by TNFα.
Conclusions: In summary, our findings reveal that TNFα sensitizes NBL cells to FasL-induced cell death by
NF-κB-mediated upregulation of Fas and unveil a new mechanism through which TNFα enhances the efficacy
of currently used NBL treatments, cisplatin and etoposide.
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Neuroblastoma (NBL) is a solid tumor that arises from
neuronal crest cells of the sympathetic nervous system.
The most common form of cancer in infancy, NBL
causes 15% of cancer-related deaths in children. The tu-
mors have remarkable heterogeneity, which become evi-
dent in the clinic where patients can show spontaneous
regression or rapid and fatal tumor progression. Over
the years, significant advances have been made in the
treatment of low- and intermediate-risk patients, thus
allowing reaching high survival rates; however, the
5-year survival rate of patients in the high-risk group is
still below 50% [1-3].
High-risk NBLs are treated with surgery, chemothe-
rapy, radiotherapy, and/or the use of biological agents.
Most of the therapeutic strategies used in NBL interfere
with cell cycle progression and DNA synthesis or func-
tion, thereby causing DNA damage and the induction of
apoptosis through the intrinsic and extrinsic apoptotic
pathways [4].
The extrinsic or Death receptor (DR) pathway is acti-
vated by cell surface receptors of the tumor necrosis fac-
tor receptor (TNFR) family, which includes receptors for
TNFα, FasL, and TNF-related apoptosis-inducing ligand
(TRAIL) [5-7]. These receptors contain a death domain
in their cytosolic tail which upon receptor activation
leads to context-dependent outcomes such as apoptosis,
necroptosis, or pro-survival signaling. The targeting of
DR signaling has been proposed and studied for the
treatment of various types of cancers [8-10]. For NBL
tumors, this strategy has been largely disregarded, pos-
sibly because caspase-8 silencing occurs in 50-70% of all
human NBLs [11-14]. However, a significant group of
NBL patients do express caspase-8 and could benefit
from treatments that induce DR activation. Given that
TNFα is able to upregulate Fas expression in human
cancer cell lines and sensitize them to FasL-induced cell
death [15-17], we sought to investigate whether TNFα
and FasL combination could be therapeutically relevant
in NBL.
We found that TNFα treatment primes a subset of
NBLs for FasL-induced cell death by triggering the NF-
κB-mediated upregulation of Fas. Moreover, TNFα pre-
treatment increased cisplatin- and etoposide-induced
caspase-8 cleavage and cell death in NBL cells that ex-
press both Fas and caspase-8. Our findings suggest that
selected NBL patients could benefit from treatments that
target TNFR1 and upregulate Fas expression.
Results
TNFα and FasL co-treatment induces cell death in
SK-N-AS cells
To ascertain whether simultaneous treatment with FasL
and TNFα induces cell death in NBL cells, we used thecaspase-8-expressing NBL cell line SK-N-AS. TNFR1
was activated with soluble TNFα and the Fas receptor
with trimeric Fc:hFasL [18-20]. Cell death assessment by
Hoechst staining showed that TNFα or FasL treatment
alone barely induced cell death (~5% and 20% respect-
ively). However, the combination of the two cytokines
caused an increase in cell death after 8 h of treatment,
as compared to treatment with TNFα or FasL alone
(Figure 1A). After 24 h, nearly all cells in the co-treatment
condition were dead. Moreover, an increase in caspase-8
and caspase-3/7 activity was observed after simultaneous
treatment with TNFα and FasL (Figure 1B-C). The use of
the caspase-8 specific inhibitor IETD or the pan-caspase
inhibitor QVD fully abrogated TNFα/FasL-induced cell
death, thereby indicating that apoptosis triggered by FasL
is the main mechanism of loss of viability (Figure 1D).
TNFα primes SK-N-AS cells for FasL-induced cell death by
upregulating Fas
Next, we analyzed whether the phenotypic effects of the
TNFα/FasL co-treatment were caused by the FasL and
TNFα receptors signaling in synergy or whether one DR
was sensitizing for apoptotic signaling by the other DR.
Sequential treatment with TNFα or FasL followed by
FasL or TNFα administration, respectively, revealed that
TNFα was able to sensitize SK-N-AS cells to FasL-
induced cell death (Figure 2A). On the contrary, FasL
pre-treatment did not sensitize the cells to TNFα. The
increase in caspase-8 activity during the co-treatment
and the abrogation of cell death when using the caspase-
8 inhibitor IETD suggested that TNFα induces molecu-
lar changes upstream of caspase-8 activation. Therefore,
to address this point, we characterized the effects of
TNFα on the expression of various components of the
DISC complex (Figure 2B). Interestingly, a significant in-
crease was observed only in Fas mRNA levels whereas
minimal variations were detected for caspase-8, FADD,
and RIP1 (Figure 2B). The increase in Fas mRNA levels
was confirmed at the protein level by Western blot as
early as 8 h after TNFα treatment (Figure 2C), which is
consistent with the increase in cell death observed after
simultaneous treatment with TNFα and FasL.
Newly synthesized Fas is exposed to the plasma
membrane and favors DISC formation
The increase in FasL-mediated cell death could be ex-
plained by exposure of the newly synthesized Fas recep-
tor to the cell surface. To test this notion, we used a cell
surface biotinylation assay to analyze the cellular dis-
tribution of Fas after TNFα treatment. An increase in
total and cell surface Fas was already observed after 4 h
of TNFα treatment, peaking at 12 h, after which the
expression was maintained for at least another 12 h
(Figure 3A). To further confirm the functionality of the
Figure 1 Co-treatment with TNFα and FasL induces cell death in SK-N-AS cells. A. SK-N-AS cells were left untreated (UT) or treated for the
indicated times with 100 ng/ml Fc:hFasL, 100 ng/ml TNFα, or both. Cell death was assessed by Hoechst staining. Right images are representative
of nuclear staining after 24 h of treatment. Scale bar, 20 μm. B-C. Caspase activity assay in SK-N-AS cells left untreated (UT) or treated for 8 h with
100 ng/ml TNFα, 100 ng/ml Fc:hFasL or both incubating with Z-IETD-Afc to measure caspase-8 (B) or Ac-DEVD-Afc to measure caspase 3/7 activity
(C). D. Cell death assay in SK-N-AS cells treated or not (UT) for 24 h with 100 ng/ml TNFα, 100 ng/ml Fc:hFasL, or both in the presence of the
caspase-8 inhibitor (50 μM IETD) or the pan-caspase inhibitor (10 μM QVD). Cell death was assessed by Hoechst staining *p ≤ 0.05; **p ≤ 0.01;
***p ≤ 0.001.
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formed before and after TNFα pre-treatment. Indeed,
FasL co-immunoprecipitated with FADD and caspase-8
only in cells pre-treated with TNFα (Figure 3B). Interest-
ingly, in the absence of this pre-treatment, we were only
able to immunoprecipitate low levels of high molecular
weight Fas (~150 kDa) and in these conditions we did
not detect caspase-8 or FADD immunoprecipitation.
The analysis of input cell lysates confirmed that caspase-
8 and −3 were cleaved only after FasL treatment and
could be increased by TNFα pre-treatment (Figure 3B).
These data demonstrate that cell surface exposure of Fas
shows similar kinetics as the newly synthesized Fas,
thereby suggesting a rapid translocation of newly synthe-
sized Fas to the surface. Furthermore, the increased cell
surface expression of Fas enhanced FasL-induced DISC
formation, which led to the activation of the extrinsic
apoptotic pathway.
TNFα-induced Fas is transcriptionally regulated by NF-κB
TNFα has been shown to induce gene expression by ac-
tivating various signaling pathways, such as those ofERK1/2, PI3K, and JNK kinases and transcription factors
like NF-κB [5,6,21]. Therefore, we proceeded to analyze
Fas expression after TNFα treatment combined with
specific inhibitors: PD98059 (ERK1/2), LY294002 (PI3K),
SP600125 (JNK), BAY 11–7082 (NF-κB), or overexpres-
sing Super Repressor (SR), a mutated form of the NF-κB
inhibitor IκBα that inhibits NF-κB signaling [22,23].
While the inhibition of ERK1/2, PI3K or JNK did not
block the upregulation of Fas by TNFα (Figure 4A), the
inhibition of the NF-κB -pathway by overexpression of
SR or treatment with BAY 11–7082 did fully abrogate
the upregulation of Fas induced by TNFα at the protein
level (Figure 4B). Other known NF-κB targets, such as
Bcl-2 [24] and c-FLIPS [25], were used as controls.
Moreover, the use of SR overexpression or treatment
with BAY 11–7082 blocked the TNFα-induced upre-
gulation of Fas mRNA or known NF-κB targets such as
c-FLIP and Bcl-2 (Figure 4C). Further assessment of
TNFα-induced gene transcription and mRNA transla-
tion was performed with the use of DNA transcription
(Actinomycin D) and mRNA translation (Cycloheximide)
inhibitors (Figure 4D-E). Both inhibitors blocked the
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Figure 2 TNFα primes for FasL-induced cell death and upregulates Fas expression. A. SK-N-AS cells were left untreated or were
pre-treated for 24 h with 100 ng/ml TNFα or 100 ng/ml Fc:hFasL and subsequently washed and left untreated (UT) or treated for 24 h with
100 ng/ml TNFα or 100 ng/ml Fc:hFasL. Cell viability was assessed by calcein AM staining. B. SK-N-AS cells were treated or not with 100 ng/ml
TNFα for the indicated times and mRNA levels of the indicated genes were assessed by qRT-PCR. mRNA expression levels were normalized
using 18S. C. Western blot of Fas expression in SK-N-AS cells treated with 100 ng/ml TNFα for the indicated times. α-Tubulin was used as
loading control. ***p ≤ 0.001.
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whereas only actinomycin D was able to inhibit TNFα-
induced upregulation of Fas mRNA. Cycloheximide did
not result in abrogation of Fas mRNA induction, thereby
confirming the direct NF-κB -mediated transcriptional
regulation of this protein (Figure 4D-E). In summary, our
results reveal that the upregulation of Fas mRNA occurs
rapidly after TNFα treatment through activation of the
NF-κB -mediated transcription of the Fas gene. Moreover,
the inhibition of Fas upregulation by the overexpression of
SR, treatment with BAY 11–7082 (Figure 4B), or by block-
ing its synthesis with actinomycin D and cycloheximide
treatment (Figure 4E) prevented the cell surface exposure
of Fas.
TNFα primes for cisplatin- and etoposide-induced
activation of caspase-8 and cell death
The FasL/Fas system has been shown to participate in
cell death mechanisms triggered by DNA-damaging
agents currently used in NBL therapy such as cisplatin
and etoposide [26,27]. Therefore, we addressed whether
TNFα treatment enhances the cytotoxic effect of these
two drugs. Cisplatin and etoposide have been shown to
induce FasL expression in NBL cells [27]. We confirmed
these observations in SK-N-AS cells, as an increase inFasL mRNA was detected after 24 h of etoposide or
cisplatin treatment (Figure 5A). Furthermore, the induc-
tion of FasL by treatment with these chemotherapeutic
agents concurred with the activation of caspase-8, as
reflected by caspase-8 cleavage (Figure 5B). Indeed,
TNFα treatment upregulated Fas expression in SK-N-AS
cells and enhanced the cleavage of caspase-8 induced by
cisplatin (Figure 5B left) and by etoposide (Figure 5B
right). We next analyzed the functional consequences of
these observations in a subset of NBL cell lines (SK-N-
AS, SK-N-SH, SH-SY5Y, and LAI-5S) and assessed cell
death by Hoechst staining (Figure 5C). Notably, only the
SK-N-AS and SK-N-SH cell lines showed an increase in
cisplatin- and etoposide-induced cell death when primed
with TNFα, whereas no changes in cell death were ob-
served for the SH-SY5Y and LAI-5S cell lines.
NBLs show heterogeneity in TNFα-induced Fas expression,
thereby explaining the priming for cisplatin- and
etoposide-induced cell death
NBLs are known to have a high degree of heterogeneity
[1-3], which may explain why some NBL cell lines are
not primed by TNFα for cisplatin- and etoposide-
induced cell death. Therefore, we assessed the expres-
sion of Fas and its modulation by TNFα treatment in a
Figure 3 TNFα-induced Fas is exposed to the cell surface and enhances FasL-induced DISC formation. A. SK-N-AS cells were treated with
100 ng/ml TNFα for the indicated times, and cell surface levels of Fas protein were assessed by cell surface biotinylation and subsequent Western
blot. Below, quantification of total and cell surface Fas expression normalized vs. matching α-Tubulin controls. B. DISC (Death inducing signaling
complex) formation assay in SK-N-AS cells pre-treated or not with 100 ng/ml TNFα and treated for 30 min with 2.5 μg/ml Fc:hFasL. The DISC
proteins were immunoprecipitated by pulling down Fc:hFasL with protein G-Sepharose and analyzed by Western blot.
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line, TNFα upregulated Fas expression in the SK-N-SH,
CHLA90, and Tet21N cell lines, as observed by flow
cytometry (Figure 6A) and Western blot (Figure 6B). Fur-
thermore, TNFα was also able to sensitize these cells to
FasL-induced apoptosis, as determined by Hoechst stain-
ing (Figure 6C) and caspase-3/7 activity (Additional file 1:
Figure S1). In contrast, the SH-SY5Y, LAI-5S, IMR32, and
SK-N-BE(2) cell lines did not show changes in Fas expres-
sion (Figure 6A-B), FasL-induced cell death (Figure 6C),
or caspase-3/7 activity (Additional file 1: Figure S1) after
TNFα treatment. Interestingly, these cells showed TNFα-
induced IκBα degradation and the upregulation of other
known NF-κB -target genes, such as Bcl-2 [24] and/or
cIAP2 [28] (Additional file 2: Figure S2A-B).
A correlation could be observed between the expres-
sion of both Fas and caspase-8, the induction of cell
death by FasL and the sensitization thereof by TNFα.
Cells that only express one of the two proteins did not
show FasL-induced cell death and could not be sensi-
tized by TNFα. However, cells that express both pro-
teins, Fas and caspase-8, did show FasL-induced cell
death and TNFα-induced sensitization. Furthermore, the
levels of Fas and caspase-8 expression concur with the
FasL-induced cell death response. CHLA90 cells, with
low levels of Fas and caspase-8, exhibit little FasL-
induced cell death when compared to Tet21N cells,
which show high levels of Fas and caspase-8 expression.Due to these high levels and the corresponding cell
death response, Tet21N cells had to be treated with
lower levels of FasL for the TNFα-induced sensitization
to become apparent, since 100 ng/ml FasL induced a
near complete cell death response (data no shown).
These findings demonstrate that although NF-κB is ac-
tivated and induces gene transcription in all the NBL cell
lines studied here, there is a subset of NBL cell lines in
which Fas expression is not upregulated in response to
TNFα treatment. These observations concur with our
previous observations in which we determined that these
cells were primed neither for cisplatin- nor etoposide-
induced cell death when targeted with TNFα.
Interferon-γ reconstitutes caspase-8, upregulates Fas
expression, and primes NBL for FasL-induced cell death
Interferon-γ (IFNγ) is known to render NBL cells sensitive
to FasL-induced cell death by reconstituting caspase-8
and upregulating Fas expression [29-31]. Here we studied
whether NBL treatment with IFNγ promotes TNFα-
induced Fas expression in cell lines that previously did not
show Fas induction in response to TNFα treatment (i.e.
SH-SY5Y and SK-N-BE(2)). We confirmed that IFNγ
upregulates caspase-8 and Fas expression in these cell
lines (Figure 7A-B). The SK-N-BE(2) cell line showed a
TNFα-induced increase in caspase-8 and Fas expression
after IFNγ treatment. However, in the SH-SY5Y cells,
TNFα did not modulate the expression of either protein.
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Figure 4 NF-κB mediates TNFα-induced Fas expression and exposure to the cell surface. A. Left panel, SK-N-AS cells were treated with
25 μM PD980059, 20 μM LY294002 or 20 μM SP600125 prior to treatment with 100 ng/ml TNFα. At the indicated times, cell surface proteins were
biotinylated, isolated, and analyzed by Western blot. Right panel, phospho-protein levels assessed by Western blot to confirm efficacy of PD980059 (PD),
LY294002 (LY), and SP600125 (SP). B. Left panel, control (Neo) and SuperRepressor/SR-IκBα-infected SK-N-AS cells were left untreated (−) or treated with
100 ng/ml TNFα for 8 h and 24 h. Cell surface proteins were biotinylated, isolated, and analyzed by Western blot. Right panel, analysis of cell surface and
total Fas levels. SK-N-AS cells were incubated with 10 μM and 25 μM of the NF-κB inhibitor BAY 11–7082 prior treatment with 100 ng/ml TNFα. Below,
quantification of total Fas expression normalized vs. matching α-Tubulin controls. IκBα degradation Western blot confirmed the efficacy of BAY 11–7082.
C. Control (Neo) and SuperRepressor/SR-IκBα-infected or control (−) and BAY 11–7082 pre-treated SK-N-AS cells were left untreated (UT) or treated with
100 ng/ml TNFα. mRNA levels of the indicated genes were assessed after 4 h by qRT-PCR. D. qRT-PCR assessment of the indicated genes, 4 h after
100 ng/ml TNFα treatment of SK-N-AS cells in combination with 20 nM actinomycin D or 1 μg/ml cycloheximide. E. Cell surface biotinylation assay in
SK-N-AS cells pre-treated with 20 nM actinomycin D or 1 μg/ml cycloheximide and treated with 100 ng/ml TNFα for the indicated times. Protein
levels were analyzed by Western blot. Below, quantification of total Fas expression normalized vs. matching α-Tubulin controls. All conditions were
pre-incubated with 10 μM of the caspase inhibitor QVD to avoid cell death-related effects.
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Figure 5 TNFα is able to sensitize NBL cell lines to cisplatin- and etoposide-induced cell death. A. FasL mRNA levels were assessed by
qRT-PCR in cisplatin- (30 μM) and etoposide- (30 μM) treated SK-N-AS cells for the indicated times. mRNA levels were normalized using 18S mRNA.
B. Caspase-8 cleavage was analyzed by Western blot in SK-N-AS cells pre-treated with 100 ng/ml TNFα for 24 h after cisplatin (30 μM) and etoposide
(30 μM) treatments. C. Cell death assay by Hoechst staining in the indicated cell lines pre-treated with 100 ng/ml TNFα for 24 h and treated with the
indicated concentrations of cisplatin (Cis) and etoposide (Eto) for 48 h. *p≤ 0.05; **p≤ 0.01; *** p≤ 0.001.
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BE(2) and SH-SY5Y cells to FasL-induced cell death
(Figure 7C) and caspase 3/7 activity (Additional file 1:
Figure S1). For the SK-N-BE(2) cells, subsequent TNFα
treatment further increased sensitization to FasL-induced
cell death. In contrast, SH-SY5Y cells, which did not show
a further increase in caspase-8 or Fas levels, did not show
further sensitization to FasL-induced cell death after
stimulation with TNFα. These data indicate that the in-
duction of Fas expression by TNFα in NBLs cannotalways be recovered by IFNγ treatment, thus pointing to
different levels of Fas regulation.
Discussion
Many patients with high-risk NBL tumors continue to
have a poor prognosis. Consequently, ongoing efforts are
being channeled into the development of new treat-
ments or the discovery of therapeutic agents that can in-
crease the efficacy of current clinical regimes—cisplatin
and etoposide being examples of such drugs [2]. Here
Figure 6 (See legend on next page.)
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Figure 6 NBLs show heterogeneous Fas expression in response to TNFα treatment. A. NBL cell lines were treated with 100 ng/ml TNFα or
left untreated (UT) for 24 h. Fas expression was analyzed by cytometry using a PE-conjugated Fas or isotype antibody. B. Cells were treated for
24 h with 100 ng/ml TNFα or were left untreated (UT). Protein expression levels were analyzed by Western blot. C. Cell death assay by Hoechst
staining in the indicated cell lines pre-treated with 100 ng/ml TNFα for 24 h and treated for another 24 h with 100 ng/ml Fc:hFasL, or 1 ng/ml
Fc:hFasL for Tet21N cells. **p ≤ 0.01; ***p ≤ 0.001.
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ceptibility to FasL-, cisplatin- and etoposide-induced cell
death through the NF-κB -mediated upregulation of Fas,
a target that has received little attention for NBL therap-
ies. The newly synthesized Fas is exposed to the cell sur-
face and incorporated into the DISC complex upon
ligand binding, thereby triggering the activation of cas-
pases and inducing apoptotic cell death.
Soluble TNFα exerts its effects through the binding
and activation of the ubiquitously expressed TNFR1 re-
ceptor [5-7,18,19]. Depending on the cellular context,
TNFα stimulation induces apoptosis, necroptosis, or pro-
survival signaling through the activation of caspases, ki-
nases, and transcription factors such as NF-κB [5-7,21].
For NF-κB activation, TNFR1 binds the adaptor protein
TRADD through interaction with its death domain. This
interaction allows the recruitment of the adapter protein
RIP1 and the E3 ligases TRAF2/5 and cIAP1/2, thereby in-
ducing the ubiquitination of RIP1. This shapes the plat-
form for recruitment and activation of the IKK complex
that induces phosphorylation of the cytoplasmic NF-κB
inhibitor IκBα, thereby targeting it for ubiquitination and
subsequent proteasomal degradation. Degradation of IκBαIso UT TNFα
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Figure 7 IFNγ renders caspase-8- and Fas-deficient NBLs sensitive to
(IFNγ) or were left untreated (UT) for 24 h. Cells were then treated or not for 2
using a PE-conjugated Fas or an isotype antibody. B. Fas and caspase-8 expre
24 h with 100 ng/ml interferon-γ (IFNγ) and treated with 100 ng/ml TNFα for
100 ng/ml IFNγ for 24 h and thereafter treated or not with 100 ng/ml TNFα fo
Fc:hFasL. *p≤ 0.05; **p≤ 0.01; ***p≤ 0.001.mediates the release of NF-κB and allows its translocation
to the nucleus where it can induce gene transcription. Ac-
cording to our data and data from others, FAS is amongst
the genes that can be induced by NF-κB. Chan et al. and
Liu et al. have previously identified the p65/RelA binding
site in the Fas promoter and confirmed TNFα-induced
NF-κB -mediated upregulation of Fas [32,33]. Here, we
were able to demonstrate the NF-κB -mediated regulation
in NBLs and discarded regulation of Fas expression by
other pathways known to be activated by TNFR1 (i.e.
ERK1/2, PI3K, and JNK).
Given the participation of the Fas/FasL system in the
mechanisms of cell death caused by DNA-damaging
agents such as cisplatin and etoposide [26,27], we
studied the possibility of improving the efficacy of these
drugs by combined treatment with TNFα. Our results
showed that TNFα pre-treatment increased cisplatin-
and etoposide-induced cell death in two of the four NBL
cell lines studied. Similarly, Benedetti et al. reported that
TNFα acts in synergy with cisplatin in renal proximal
tubular cells, inducing an increase in cell death by
prolonging JNK activation and inhibiting NF-κB trans-
location to the nucleus [34,35]. However, our dataC
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etoposide-induced cell death depends on NF-κB -mediated
induction of Fas expression and caspase-8 cleavage.
Remarkably, not all the NBL cell lines studied were
primed by TNFα for cisplatin- and etoposide-induced
cell death. To predict the benefit of the TNFα combi-
nation therapy, we analyzed the expression of Fas and
the modulation thereof by TNFα in a set of eight NBL
cell lines. In four of the eight NBL cell lines, TNFα up-
regulated Fas expression. Furthermore, we observed that
only the cell lines that showed TNFα-induced upregula-
tion of Fas expression also displayed TNFα-induced
priming to FasL-, cisplatin-, and etoposide-induced cell
death. The cell lines that showed TNFα-induced priming
also displayed Fas and caspase-8 expression, whereas cell
lines that were not primed by TNFα showed the expres-
sion of only one of the two proteins. The response to
TNFα treatment was not related to other frequent NBL
alterations, such as MYCN amplification or p53 func-
tional status (see Table 1).
The mechanism by which Fas is silenced in NBL and
why some cell lines do not respond to the TNFα-
induced Fas regulation remains to be clarified. In the
NBL cell lines addressed, we confirmed NF-κB activation
after TNFα treatment and detected the induction of
other known NF-κB target genes, such as cIAP2 and
Bcl-2 [24,28]. One possible mechanism to explain this
lack of Fas induction is that TNFα treatment stimulates
the formation of different NF-κB heterodimers or NF-κB
was post-transcriptionally modified, which may drive
specific gene expression [42]. An alternative mechanism
to account for the incapacity of TNFα to induce Fas ex-
pression can be found at the level of epigenetic regula-
tion of the Fas gene. Methylation of the Fas promoter
has been reported in various types of tumors, including
NBL [43-45]. IFNγ has been shown to restore caspase-8
and Fas expression in NBL cells [29-31,46,47] and to
render them sensitive to FasL treatment. Consequently,
IFNγ may also prime caspase-8- or Fas-deficient NBL
cells for the TNFα combination therapy. Indeed, we
confirmed that IFNγ primes these NBL cells for FasL-Table 1 Neuroblastoma characteristics and their modulation
MYCN no
SK-N-AS
Expression Fas +
Caspase-8 ++
p53 N [38]
TNFα-induced Fas ++
Sensitization to etoposide/cisplatin ++
FasL-induced cell death UT +
TNFα +++
Abbreviations: F Functional, N Non-functional, NA Not available.induced cell death. However, IFNγ treatment did not
sensitize all the NBL cell lines to the TNFα-induced up-
regulation of Fas. These findings suggest that the expres-
sion of Fas in NBLs is regulated at various levels and
that it differs between NBLs.
Recent studies have described the benefits of TNFα in
combination with doxorubicin [48] or melphalan [49]
for the treatment of solid tumors. Due to its low tole-
ration in systemic treatment, various TNFα fusion pro-
teins have been developed for localized treatment [50],
some of which show promise and have entered clinical
trials [49,51,52]. These findings break ground for the use
of TNFα in the treatment of NBL in combination with
cisplatin and etoposide.
Our results suggest that NF-κB -mediated upregula-
tion of Fas by TNFα could be a new approach for the
treatment of NBL patients. These findings are in contra-
diction to the current dogma in which NF-κB inhibition
is seen as a strategy for cancer treatment, since NF-κB
has been implicated in promoting cancer initiation,
development, and metastasis [53,54]. NF-κB activation is
known to promote cell survival by upregulating anti-
apoptotic proteins, such as Bcl-2, c-FLIP, and cIAP2
thereby inhibiting DR-induced apoptosis [24,25,28]. How-
ever, NF-κB is also able to promote apoptosis through the
induction of pro-apoptotic proteins, such as Fas [32,33],
Bax [55], DR5 [56], and DR6 [57]. Our study supports the
evidence that NF-κB triggers pro-apoptotic signaling in a
subset of NBL cells through Fas upregulation, which tips
the scale towards apoptotic cell death.
Conclusions
The results of this study contribute to our understanding
of Fas expression, its regulation by TNFα in a NBL setting,
and its implications in the treatment of NBL tumors. Al-
though TNFα is mostly known for its pro-survival signal-
ing [24,25,28], our results indicate that this cytokine has
the capacity to prime caspase-8- and Fas-expressing NBLs
for cisplatin- and etoposide-induced cell death. These
findings pave the way for a new approach to improve
clinical response to current NBL treatments.by TNFα
n-amplified [36,37] MYCN amplified [36,37]
SK-N-SH CHLA90 SH-SY5Y LAI-5S SK-N-BE(2) IMR32 Tet21N
+ +/− +/− - - + ++
++ +/− - +/− +/− - ++
F [39] N [40] F [39] N [41] N [40] F [39] F [39]
+ + - - - - ++
+ NA - - NA NA NA
+/− - - - - - ++
+++ + - - - - +++
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Reagents
Unless stated otherwise, all biochemical reagents were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). Recom-
binant Fc:hFasL was a generous gift of Dr. Pascal Schneider
(University of Lausanne, Epalinges, Switzerland). Recom-
binant human TNFα and IFNγ were supplied by Biotrend
(Köln, Germany). PD98059, SP600125, BAY 11–7082,
Z-IETD-FMK, and Q-VD-OPH were purchased from
Merck Millipore (Billerica, MA, USA).
Cell culture
The human NBL cell lines SK-N-AS, LAI-5S, IMR32,
SK-N-BE(2), and SH-SY5Y and the renal epithelial cell line
HEK293T were cultured in DMEM (Thermo Fisher
Scientific, Waltham, MA, USA) supplemented with 10% or
15% (SH-SY5Y) heat-inactivated FBS (FBSi, Thermo Fisher
Scientific). The NBL cell lines SK-N-SH and CHLA90 were
cultured in IMDM (Thermo Fisher Scientific) supple-
mented with 20% FBSi. The NBL cell line Tet21N was
maintained in RPMI 1640 (Thermo Fisher Scientific) sup-
plemented with 10% FBSi, 25 mM HEPES (Thermo Fisher
Scientific), 200 μg/ml geneticin (G418), 0.5 μg/ml ampho-
tericin B, and 10 μg/ml hygromycin B. Cell culture media
was supplemented with 100U/ml penicillin and 100 μg/ml
streptomycin (Thermo Fisher Scientific). Cultures were
maintained at 37°C in a saturated atmosphere of 95%
air and 5% CO2. CHLA90 cells were acquired from
the Children’s Oncology Group Cell Line repository.
SK-N-BE(2) and LAI-5S cells were from the Public
Health England Culture Collections (Salisbury, UK).
Tet21N cells were a kind gift from Dr. Manfred Schwab
(DKFZ, Heidelberg, Germany). All other cell lines were
acquired from the American Type Tissue Collection
(ATCC, Manassas, VA, USA).
Hoechst staining
After the indicated treatments, cells were fixed with 2%
paraformaldehyde, permeabilized with 0.1% Triton™ X-100,
and stained with 0.05 μg/ml Hoechst 33342. Cell death
was assessed by counting viable and dead cells, by discri-
minating condensed and fragmented nuclei (apoptotic nu-
clear morphology type II), as described by Yuste et al. [58].
Quantification was performed in blind testing, and at least
500 cells were counted per condition.
Caspase activity
After the indicated treatments, cells were harvested,
washed with ice-cold PBS, lysed in caspase activity buffer
(20 mM HEPES-NaOH, pH7.2, 10% sucrose, 150 mM
NaCl, 5 mM EDTA, 1% Igepal CA-630, 0.1% CHAPS,
and 1× EDTA-free Complete protease inhibitor mixture),
and insoluble fractions were removed by centrifugation.
The protein concentration of the lysate was quantifiedusing the Lowry-based DC protein assay (Biorad, Hercules,
CA, USA). Next, caspase activity was assessed by incu-
bating 10 μg protein at 37°C in caspase activity buffer sup-
plemented with 10 mM DTTand 50 μM of the fluorogenic
substrate Z-IETD-Afc for caspase-8 activity or Ac-DEVD-
Afc for caspase-3/7 activity (Merck Millipore). Caspase ac-
tivity was assessed in a fluorometer using excitation and
emission wavelengths of 405 nm and 535 nm, respectively.
Calcein AM
After the indicated treatments, cells were incubated for
1 h at 37°C with 1 μM Calcein AM (Merck Millipore) di-
luted in DPBS (Thermo Fisher Scientific). Fluorescence
was then assessed in a fluorometer using excitation and
emission wavelengths of 485 nm and 535 nm, respectively.
qRT-PCR
After treatment, cells were harvested, washed with ice-cold
PBS, and RNA was isolated using the RNeasy Mini kit
(Qiagen, Hilden, Germany) following the manufacturer’s
instructions. Next, the RNA was retrotranscribed to cDNA
using the High Capacity RNA-to-cDNA™ Kit (Thermo
Fisher Scientific) and subjected to PCR analysis using
Taqman® probes and Universal PCR Master Mix (Thermo
Fisher Scientific). Taqman® probes: Fas (Hs00531110_m1),
Caspase-8 (Hs01018151_m1), FADD (Hs00538709_m1),
RIP1 (Hs00169407_m1), FasL (Hs00181225_m1), c-FLIP
(Hs01116280_m1), Bcl-2 (Hs00608023_m1), and 18S
(Hs03928990_g1).
Cell surface biotinylation
Cell surface proteins were biotinylated, isolated, and col-
lected by using the Pierce® Cell Surface Protein Isolation
Kit (Thermo Fisher Scientific), following the manufac-
turer’s instructions, with the only exception of equalizing
protein quantity and concentration before immunoprecip-
itation. Protein levels were determined by Western blot.
DISC immunoprecipitation
For Fas DISC analysis, cells were treated with Fc:hFasL
(2.5 μg/ml) for 30 min. The cells were then washed with
ice-cold PBS, harvested, and lysed in ice-cold Triton lysis
buffer (NaCl 150 mM, EDTA 10 mM, Tris–HCl pH7.4
10 mM, 1% Triton™ X-100, 1x EDTA-free complete prote-
ase inhibitor cocktail (Roche, Basel, Switzerland)). After
lysate clearance by centrifugation, Fc:hFasL was im-
munoprecipitated from the supernatant by incubation
with protein G-Sepharose beads for 1 h on an orbital
shaker at 4°C. Next, the beads were washed 5x with ice-
cold Triton lysis buffer, and the immunocomplexes were
collected with elution buffer (Citrate 0.1 M, pH2.5). The
pH was adjusted by adding 1/6 neutralizing buffer (Tris
HCl 1 M, pH8.5). Protein levels were determined by
Western blot.
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Cells were harvested, washed with ice-cold PBS, and lysed
in ice-cold Triton lysis buffer or boiling SET buffer (Tris–
HCl pH7.4 10 mM, EDTA 1 mM, NaCl 150 mM, 1%
SDS). Insoluble fractions were removed by centrifugation,
and protein concentration of the supernatant was quan-
tified. The cell lysates obtained (25 μg of protein) were re-
solved in SDS-polyacrylamide gels. Next, proteins were
transferred onto PVDF Immobilon-P membranes (Merck
Millipore) by electrophoresis. Membranes were blocked
with 5% non-fat dry milk in 1× TBS and 0.1% Tween-20
and probed with the appropriate primary antibodies
[anti-Fas (C-20), anti-FADD (S-18), anti-c-FLIPS/L(H-202),
anti-IκBα (C-21), anti-cIAP2 (H-85) (Santa Cruz,
Biotechnology, Santa Cruz, CA, USA), anti-α-Tubulin
(Sigma-Aldrich), anti-Bcl-2 (Dako, Agilent Technologies,
Santa Clara, CA, USA), anti-Caspase-3 and anti-Caspase-8
(Cell Signaling Technologies, Beverly, MA, USA)] and
the corresponding peroxidase-conjugated secondary anti-
bodies (Sigma-Aldrich).
Plasmids
The Super-repressor IκBα (SR) cDNA was subcloned
from the validated pcDNA3 expression vector [22,59]
into the lentiviral pWPI expression vector. SR was ex-
pressed under the control of the constitutively active
EF-1 Alpha promoter.
Lentiviral production and cell infection
Lentiviruses were produced in HEK293T cells by Lipofec-
tamine 2000 (Thermo Fisher Scientific) co-transfection of
pWPI-derived constructs, pSPAX2, and pM2G in a 3:2:1
ratio, respectively. Cells were allowed to generate lentivi-
ruses for 48 h, after which the lentivirus-bearing medium
was collected and passed through a Whatman® 45 μm
filter (GE Healthcare, Little Chalfont, UK). For infection,
the lentivirus-bearing medium was added to the host cells
in combination with 8 μg/ml polybrene. Infection effi-
ciency was assessed by direct counting of GFP-positive
cells, and infection was repeated until an efficiency
of ≥95% was reached.
Flow cytometry
After the indicated treatments, cells were detached with
cell dissociation buffer (PBS, 5 mM EDTA), harvested,
washed 2× with ice-cold PBS and 1× with ice-cold FACS
buffer (PBS, 2% FBSi, 0.02% sodium azide), and then
incubated for 30 min on ice with a PE-conjugated mo-
noclonal antibody against Fas or its matched isotype
(Becton Dickinson, Franklin Lakes, NJ, USA). Thereafter,
cells were washed 2× and resuspended in ice-cold FACS
buffer. Fas expression was assessed by a FACSCalibur™
flow cytometer (Becton Dickinson).Statistical analysis
All the experiments were repeated at least three times.
Values are expressed as mean ± SD. Statistical signifi-
cance was determined by one-way or two-way ANOVA
using GraphPad Prism v5 (GraphPad Software, La Jolla,
CA, USA).Additional files
Additional file 1: Figure S1. TNFα pre-treatment sensitizes a subset of
NBLs to FasL-induced caspase-3/7 activity. The indicated cell lines were
pre-treated or not for 24 h with 100 ng/ml TNFα and were left untreated
(UT) or treated for 4 h with 100 ng/ml Fc:hFasL, or 1 ng/ml Fc:hFasL for
Tet21N cells. Before Fc:hFasL treatment, SH-SY5Y and SK-N-BE(2) cells
were treated for 24 h with 100 ng/ml interferon-γ (IFNγ) or not (UT), and
an additional 24 h with 100 ng/ml TNFα or were left untreated (UT).
DEVDase activity was assessed using 10 μM Ac-DEVD-Afc as substrate.
*p ≤ 0.05; **p≤ 0.01; ***p ≤ 0.001.
Additional file 2: Figure S2. NF-κB is functional in all NBL cell lines.
A. Cells were left untreated (−) or were treated with 100 ng/ml TNFα for
the indicated times. IκBα degradation was assessed by Western blot.
B. Expression of the NF-κB -target genes cIAP2 and Bcl-2 were analyzed
by Western blot in NBL cell lines left untreated (UT) or treated with
100 ng/ml TNFα for 24 h.Competing interests
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